An Intensive QT/QTc Study to Investigate the Effects of Rovalpituzumab Tesirine on Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer
Latest Information Update: 28 Sep 2018
At a glance
- Drugs Rovalpituzumab tesirine (Primary)
- Indications Small cell lung cancer
- Focus Adverse reactions
- Sponsors Stemcentrx
- 20 Sep 2018 Status changed from active, no longer recruiting to completed.
- 12 Jun 2018 Planned End Date changed from 1 Jun 2018 to 1 Oct 2018.
- 12 Jun 2018 Planned primary completion date changed from 1 Apr 2018 to 1 Oct 2018.